Crestor Anesthesia and Perioperative Interaction: What Patients and Clinicians Need to Know

Should You Take Crestor Before Surgery?

Most patients should take rosuvastatin on the morning of surgery with a small sip of water. Stopping statins abruptly before an operation can trigger a rebound inflammatory state that raises the risk of perioperative myocardial infarction. The 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation states clearly that statins should be continued in patients currently receiving them who are undergoing surgery [1].

Why Continuation Matters

A meta-analysis published in the European Heart Journal found that perioperative statin use was associated with a 38% reduction in 30-day all-cause mortality after major vascular surgery [2]. The benefit is not trivial. Patients who stopped statins in the 30 days before surgery faced significantly higher rates of postoperative myocardial infarction compared with those who continued.

Rosuvastatin's half-life of roughly 19 hours means a single missed dose on the day of surgery reduces plasma levels by about half. For a patient on 40 mg daily, that drop may be clinically relevant if the operation extends overnight [3].

The NPO Rule and Oral Statins

Standard nil-per-os (NPO) protocols restrict solid food for 6 to 8 hours before general anesthesia, but most anesthesiology societies permit oral medications with up to 150 mL of water up to 2 hours before induction [4]. Rosuvastatin tablets are small and easily swallowed with a sip. Anesthesiologists at HealthRX-affiliated facilities routinely clear rosuvastatin for preoperative administration under this protocol.

Rosuvastatin and Anesthetic Drug Interactions

Neuromuscular Blocking Agents

Rosuvastatin does not directly inhibit or induce the enzymes that metabolize standard neuromuscular blockers such as succinylcholine, rocuronium, or vecuronium. No pharmacokinetic interaction is expected based on the rosuvastatin prescribing information reviewed on the FDA label [3]. However, myopathy induced by statins can reduce baseline muscle mass and neuromuscular reserve, which may subtly alter the clinical response to neuromuscular blockade in patients already showing subclinical CK elevation.

Volatile Anesthetics and Myopathy Risk

Isoflurane, sevoflurane, and desflurane are not known to directly interact with rosuvastatin pharmacokinetically. Rosuvastatin is metabolized minimally by CYP2C9 and is not a substrate of CYP3A4, which differentiates it from simvastatin and lovastatin [3]. This means volatile agents that weakly induce hepatic enzymes pose less of a pharmacokinetic concern with rosuvastatin than with other statins.

Volatile anesthetics cause a degree of skeletal muscle depression. Combined with the myopathy risk inherent to statin use, the theoretical additive effect on muscle tissue is worth monitoring in high-dose rosuvastatin patients (20 to 40 mg range). A 2013 study in Anesthesiology examining statin myotoxicity in surgical patients noted that CK elevations occurred in 4.7% of patients on high-dose statins postoperatively, most resolving within 5 days without sequelae [5].

Propofol and Hepatic Considerations

Propofol is the most common induction agent worldwide. It undergoes rapid hepatic and extrahepatic metabolism via glucuronidation. Rosuvastatin is also partly metabolized in the liver and excreted primarily via bile [3]. There is no documented direct pharmacokinetic interaction between propofol and rosuvastatin. Still, patients with pre-existing hepatic impairment taking rosuvastatin should have liver function tests reviewed before procedures requiring propofol infusion over extended durations, since both agents place some demand on hepatic clearance pathways.

Rhabdomyolysis: Perioperative Risk Assessment

Baseline Risk Factors

Rhabdomyolysis from rosuvastatin is rare but serious. The FDA label reports an incidence of myopathy (CK > 10 times the upper limit of normal) of approximately 0.1% at approved doses [3]. In the surgical setting, that baseline risk compounds when multiple triggers overlap.

Risk factors that increase perioperative rhabdomyolysis probability include [6]:

• Rosuvastatin dose of 20 mg or higher
• Concomitant use of gemfibrozil (fibrates raise rosuvastatin AUC by up to 2-fold)
• Renal impairment (eGFR <30 mL/min/1.73 m²)
• Major trauma, crush injury, or prolonged immobility during surgery
• Dehydration and hemodynamic instability intraoperatively
• Hypothyroidism, undiagnosed before surgery

JUPITER Trial Context

The JUPITER trial (N=17,802) established rosuvastatin 20 mg as effective for primary cardiovascular prevention, with a hazard ratio of 0.56 for major cardiovascular events versus placebo [7]. The trial also reported that myopathy occurred in 0.08% of the rosuvastatin arm versus 0.05% in placebo over a median 1.9 years, confirming that absolute myopathy risk is low even at 20 mg. Still, JUPITER excluded patients undergoing major surgery, so perioperative extrapolation requires clinical judgment.

Postoperative Monitoring Protocol

For patients on rosuvastatin 20 to 40 mg undergoing major surgery (cardiac, vascular, orthopedic with tourniquet), a reasonable postoperative monitoring approach includes:

• CK check at 24 to 48 hours if the patient reports muscle pain or weakness
• Renal function panel (creatinine, BUN) at the same interval in high-risk patients
• Urine myoglobin if CK exceeds 5,000 IU/L
• Temporary rosuvastatin hold only if CK exceeds 10 times the upper limit of normal or acute kidney injury is present [3]

Rosuvastatin and Anesthesia in Cardiac Surgery

Coronary Artery Bypass Grafting

Cardiac surgery patients on statins occupy a special category. The ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) group of trials and subsequent analyses have shown that pre-procedural statin loading reduces myocardial injury markers [8]. While ARMYDA focused on atorvastatin, the class effect supports rosuvastatin continuation before coronary artery bypass grafting.

A 2021 observational cohort study published in JAMA Cardiology (N=4,391 CABG patients) found that patients who received statins within 24 hours of surgery had a 28% lower rate of postoperative atrial fibrillation compared with those who did not [9]. Postoperative atrial fibrillation complicates up to 30% of CABG procedures and extends ICU stays by a mean of 1.4 days.

Cardiopulmonary Bypass and Statin Pharmacokinetics

Cardiopulmonary bypass dilutes plasma drug concentrations due to circuit priming volumes of 1.4 to 1.8 liters. Rosuvastatin's volume of distribution is approximately 134 liters, so hemodilution during bypass causes only a modest transient reduction in free drug levels [3]. No dose adjustment is established for intraoperative bypass, and the standard practice is to resume oral rosuvastatin as soon as the patient tolerates oral intake postoperatively.

Can I Drink Alcohol on Crestor?

Moderate alcohol consumption (up to 1 drink per day for women, 2 for men per CDC definitions) does not produce a direct pharmacokinetic interaction with rosuvastatin [10]. Both rosuvastatin and alcohol are processed through hepatic pathways, but they use different enzyme systems. Alcohol primarily involves alcohol dehydrogenase and CYP2E1, while rosuvastatin uses CYP2C9 to a minor degree.

Hepatotoxicity Risk

Heavy alcohol use raises baseline alanine aminotransferase (ALT) levels independently. Rosuvastatin itself causes persistent ALT elevations greater than 3 times the upper limit of normal in fewer than 1% of patients in clinical trials [3]. Combining heavy alcohol consumption (more than 14 drinks per week) with rosuvastatin creates an additive hepatic stress that the ACC/AHA lipid guidelines recommend avoiding [11].

Practical Advice for Surgical Patients

Patients should disclose alcohol intake to their anesthesiologist before surgery. Chronic heavy alcohol use affects hepatic enzyme induction, prolongs some anesthetic drug effects, and raises perioperative bleeding risk through platelet dysfunction. A patient on rosuvastatin who drinks heavily should have LFTs checked before elective surgery. If ALT or AST exceeds 3 times the upper limit of normal, the rosuvastatin dose should be reviewed or held pending evaluation [3].

Drug Interactions That Matter Perioperatively

Rosuvastatin has several established pharmacokinetic interactions relevant to the hospital and surgical setting [3]:

Cyclosporine

Cyclosporine, used in transplant patients and occasionally in autoimmune disease, increases rosuvastatin AUC by approximately 7-fold. Patients on cyclosporine should not exceed 5 mg of rosuvastatin daily per FDA labeling [3]. In the perioperative period, transplant patients arriving on cyclosporine require a specific rosuvastatin dose review before any procedure.

Antacids and Aluminum/Magnesium Hydroxide

Antacids given perioperatively (commonly used for aspiration prophylaxis as sodium citrate) may reduce rosuvastatin plasma levels by approximately 54% when given simultaneously [3]. Spacing administration by at least 2 hours minimizes this interaction. This is practically important because sodium citrate or ranitidine is often given 30 to 60 minutes before elective general anesthesia.

Warfarin and Anticoagulation Management

Rosuvastatin potentiates the anticoagulant effect of warfarin by inhibiting CYP2C9-mediated warfarin metabolism. INR can rise by 10 to 15% when rosuvastatin is added to warfarin [3]. For surgical patients bridging off warfarin, any change in rosuvastatin dose (including temporary discontinuation) may paradoxically shift INR back downward. Anticoagulation management teams need to know about any statin dose changes during the perioperative period.

Gemfibrozil

Gemfibrozil is sometimes co-prescribed for mixed dyslipidemia. It inhibits OATP1B1 transport of rosuvastatin, raising rosuvastatin AUC by up to 2.2-fold [3]. This combination is not specifically contraindicated (unlike with simvastatin), but the prescribing information recommends dose caution. Perioperative myopathy risk is elevated in patients on this combination.

Statin-Naive Patients Starting Rosuvastatin Before Surgery

Prophylactic Statin Loading

Some surgical teams initiate statins in statin-naive patients before major vascular procedures to obtain the pleiotropic anti-inflammatory and endothelial-stabilizing effects. A 2009 randomized controlled trial published in the New England Journal of Medicine (the DECREASE-III trial, N=497) found that fluvastatin XL 80 mg given perioperatively reduced the composite of cardiovascular death and myocardial infarction by 47% in vascular surgery patients (P<0.001) [12]. While the specific agent was fluvastatin, the class evidence supports the concept.

Whether to start rosuvastatin de novo before an operation depends on the urgency of surgery. Elective vascular procedures allow a 2 to 4 week preoperative window for initiation. Emergency surgery does not.

Timing of Initiation

The ACC/AHA 2014 Perioperative Guideline notes that initiating statin therapy is reasonable (Class IIa, Level of Evidence B) in patients undergoing vascular surgery, even if not previously indicated by lipid levels [1]. A minimum of 7 days of therapy before surgery allows some degree of pleiotropic effect, though full lipid-lowering requires 4 to 6 weeks.

Special Populations

Asian Patients

Asian patients have approximately 2-fold higher rosuvastatin plasma concentrations than white patients at equivalent doses due to differences in OATP1B1 and BCRP transporter expression [3]. The FDA label recommends initiating rosuvastatin at 5 mg in Asian patients. This pharmacogenomic difference also affects perioperative myopathy risk. Asian patients on 20 to 40 mg of rosuvastatin should be flagged for closer CK monitoring postoperatively.

Patients With Chronic Kidney Disease

Rosuvastatin dose should not exceed 10 mg daily in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) who are not on hemodialysis [3]. This population is at higher risk for perioperative AKI, which itself concentrates rosuvastatin and raises myopathy risk. Nephrology or pharmacy consultation is appropriate before major surgery in this group.

Elderly Patients

Age alone is not a contraindication to rosuvastatin continuation perioperatively. The ACC/AHA 2018 Cholesterol Guideline supports statin use in patients aged 75 and older with established atherosclerotic cardiovascular disease [11]. Elderly patients do have higher baseline myopathy risk, however, particularly if they are frail, have low muscle mass, or take multiple interacting medications.

Practical Perioperative Checklist for Rosuvastatin Patients

Before any elective surgical procedure, rosuvastatin patients benefit from a structured review:

1. Confirm current dose (5, 10, 20, or 40 mg) and duration of use
2. Check for co-prescriptions of cyclosporine, gemfibrozil, or warfarin
3. Review LFTs and CK if the patient reports new muscle aches
4. Confirm the patient's ethnicity for OATP1B1-related dose risk
5. Assess renal function; hold rosuvastatin only if eGFR <30 and dose exceeds 10 mg
6. Advise the patient to take rosuvastatin with a sip of water on the morning of surgery, separated by 2 hours from any antacid aspiration prophylaxis
7. Resume rosuvastatin with the first postoperative oral intake
8. Check CK and creatinine at 24 to 48 hours if major muscle trauma, prolonged tourniquet time, or hemodynamic instability occurred intraoperatively